Ranitidine


Article Author:
Katie Morgan


Article Editor:
Rajni Ahlawat


Editors In Chief:
Chaddie Doerr


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Frank Smeeks
Kristina Soman-Faulkner
Radia Jamil
Patrick Le
Sobhan Daneshfar
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Nazia Sadiq
Hajira Basit
Phillip Hynes
Tehmina Warsi


Updated:
1/13/2019 10:38:21 PM

Indications

Ranitidine is FDA-approved for both adults and children aged 1 month to 16 years. Ranitidine, over-the-counter for self-care use without a prescription, is only FDA-approved in children older than 12 years.

FDA-Approved Ranitidine Indications

  • Benign gastric ulcer disease, short-term, and maintenance
  • Duodenal ulcer disease, short-term, and maintenance
  • Erosive esophagitis
  • Hypersecretory conditions (e.g., Zollinger-Ellison, systemic mastocytosis, multiple endocrine adenoma syndrome)  
  • Gastroesophageal reflux disease (GERD)
  • Non-ulcer dyspepsia, indigestion, heartburn, and sour stomach

Non-FDA-Approved Ranitidine Indications

  • Anaphylaxis[1][2]
  • NSAID-induced ulcer prophylaxis[3]
  • Stress ulcer prophylaxis[4]
  • Taxane-related urticaria prophylaxis[5]
  • Aspiration prophylaxis during obstetric anesthesia[6]

Mechanism of Action

Mechanism

Ranitidine is a competitive inhibitor of histamine H2-receptors. The reversible inhibition of H2-receptors in gastric parietal cells results in a reduction in both gastric acid volume and concentration. Ranitidine’s acid-lowering effect is more pronounced for basal and nocturnal acid secretion than it is for food-stimulated acid secretion. Additional indirect effects of ranitidine are decreased pepsin secretion and increased nitrate-reducing bacterial flora.

Pharmacokinetics and Pharmacodynamics

When dosed orally, ranitidine has a bioavailability of 50%, which is relatively unaffected by food. The peak levels occur 2 to 3 hours post-administration for oral administration and occur 15 minutes after intramuscular administration. Ranitidine is primarily excreted unchanged in the urine, with a half-life ranging from 2.5 to 3 hours, and because of the renal elimination, the half-life may increase to 4 to 5 hours in patients with kidney dysfunction.

Administration

Oral

Ranitidine is available as tablets, capsules, or oral syrup. Ranitidine solution or the dissolved tablet may be mixed with select enteral tube feeding solutions. [7] 

Intramuscular (IM)

Administer as an undiluted solution.  

Intravenous (IV)  

Intermittent IV bolus: Dilute with a compatible IV solution prior to use to a maximum concentration of 2.5 mg/mL. Then the solution may be administered at a maximum rate of 10 mg per minute.

Intermittent IV infusion: Dilute with a compatible IV solution prior to use to a maximum concentration of 0.5 mg/mL. Then the solution may be administered at a maximum rate of 2.5 to 3.5 mg per minute.

Continuous IV infusion: Dilute 150 mg ranitidine in 250 mL of a compatible IV solution. This solution then may be administered at a rate of 6.25 mg per hour. For patients with Zollinger-Ellison disease, a faster infusion rate may be required.  Dilute prior to use to a maximum concentration of 2.5 mg/mL. Then the infusion may be started at a rate of 1 mg/kg per hour to a maximum dose of 2.5 mg/kg per hour. Ranitidine may be added to total parenteral nutrition. However, its stability varies greatly depending on the specific ingredients, concentrations, and packaging of the final product.[8]

Adverse Effects

The initial clinical trials for ranitidine reported the following adverse effects following oral or parenteral administration (frequency not defined):

  • Central nervous system (CNS): Malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, and hallucinations.
  • Cardiovascular: Tachycardia, bradycardia, asystole, atrioventricular block, and premature ventricular beats. Bradycardia may be more frequent with rapid intravenous administration and in patients with cardiac rhythm disturbances.
  • Gastrointestinal (GI): Constipation, diarrhea, nausea, vomiting, abdominal discomfort, pancreatitis.
  • Hepatic: Hepatocellular, cholestatic, or mixed hepatitis; hepatic failure
  • Musculoskeletal: Myalgia, arthralgia
  • Hematologic: Leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, agranulocytosis
  • Endocrine: Decreased libido, impotence, galactorrhea, gynecomastia
  • Integumentary: Rash, alopecia, vasculitis
  • Respiratory: Pneumonia
  • Renal: Increased serum creatinine, acute interstitial nephritis
  • Other: Hypersensitivity reactions, anaphylaxis

Transient pain at the site of intramuscular (IM) injection has been reported. Transient local burning or itching has been reported with intravenous (IV) administration of ranitidine.  

The 2015 Beers Criteria list identifies ranitidine as a therapy that may potentially trigger or exacerbate delirium in adults older than 65 years of age. Caution should be used when treating the elderly with ranitidine. [9]

Long-term use of ranitidine for greater than 2 years may also be associated with vitamin B12 deficiency. [10]

Pregnancy

Ranitidine is known to cross the placenta; however, it is still commonly used when pregnant patients require acid-suppressing therapy. Of note, increasing studies are revealing a correlation between acid-suppressing therapy use during pregnancy and the development of childhood asthma. [11] Likewise, ranitidine is excreted into breastmilk, and the risks and benefits of use should be discussed prior to initiating therapy.

Contraindications

Ranitidine is contraindicated in patients who have previously experienced a hypersensitivity reaction to ranitidine or any of the product components. Small case series and analyses demonstrate conflicting results regarding cross-sensitivity among H2-receptor antagonists; caution is advised.  Due to differences and similarities between the chemical structures, there is speculation that some H2 blockers have less risk of cross-reactivity than others. [12][13][14]

Furthermore, patients with any history of acute porphyria should avoid ranitidine because it may trigger porphyric events.

Clinicians urge patients to seek professional medical care and contraindicate the over-the-counter product when they have difficulty or pain when swallowing food or have blood in vomit or stool. Concurrent use is contraindicated with other acid reducers, kidney disease, or in patients younger than 12 years old.

Monitoring

Efficacy Parameters

Patients should notice an improvement in symptoms. Laboratory signs of improvement would include an increase in gastric pH. For GI bleeding, the goal gastric pH is typically greater than 4. The goal gastric acid secretion in Zollinger-Ellison disease is less than 10 mEq per hour.

Additional Monitoring

For patients receiving ranitidine IV at total daily doses greater than 400 mg, daily monitoring of liver function tests (aspartate aminotransferase and alanine aminotransferase) may be warranted. For acutely ill patients, serum creatinine may also be measured to provide information for renal dose adjustments as well as to monitor for potential nephrotoxicity. When there is a concern of GI bleeding, further monitoring may include occult blood tests, hemoglobin, and hematocrit.

Toxicity

Severe toxicity to ranitidine is rare, and there currently is no antidote for ranitidine overdose. Patients may present with CNS depression or severe hypotension. Supportive treatment and monitoring based on the presenting symptoms may be warranted.

Enhancing Healthcare Team Outcomes

Guidelines and Recommendations

The 2015 American Academy of Allergy, Asthma, and Immunology (AAAAI), and American College of Allergy, Asthma, and Immunology (ACAAI) anaphylaxis practice parameter describe inadequate evidence for the use of H2-blockers in the treatment of anaphylaxis; however, H2-blockers can be considered adjunct therapy after the administration of epinephrine.[1][2] (Level II)

The 2009 American College of Gastroenterology guideline for the prevention of NSAID-related ulcer complications conclude that double-strength H2-blockers may reduce the risk of NSAID-induced endoscopic peptic ulcers. However, this guideline also concludes that H2 blockers are inferior to proton pump inhibitors for this indication.[3] (Level II)

The 2016 Surviving Sepsis Campaign guidelines recommend H2-blockers or proton pump inhibitors be used in patients with risk factors for stress ulcer prophylaxis.[4] (Level II)

The 2016 American Society of Anesthesiologists guideline for obstetric anesthesia suggest consideration of non-particulate antacids, H2 blockers and/or metoclopramide to prevent aspiration.[6] (Level II)


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Ranitidine - Questions

Take a quiz of the questions on this article.

Take Quiz
Ranitidine belongs to which of the following drug classes?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is true of ranitidine?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Ranitidine acts by doing which of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the mechanism of action of ranitidine?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
In what class of drugs is ranitidine?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the appropriate route of administration of ranitidine in a patient with a duodenal ulcer who is nothing per os (NPO)?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which drug is available as an injection?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient is taking both omeprazole and ranitidine and calls to ask how these medications work differently. Which statement best describes the mechanism of action of ranitidine?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following generic drugs is branded Zantac?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Ranitidine - References

References

Lieberman P,Nicklas RA,Oppenheimer J,Kemp SF,Lang DM,Bernstein DI,Bernstein JA,Burks AW,Feldweg AM,Fink JN,Greenberger PA,Golden DB,James JM,Kemp SF,Ledford DK,Lieberman P,Sheffer AL,Bernstein DI,Blessing-Moore J,Cox L,Khan DA,Lang D,Nicklas RA,Oppenheimer J,Portnoy JM,Randolph C,Schuller DE,Spector SL,Tilles S,Wallace D, The diagnosis and management of anaphylaxis practice parameter: 2010 update. The Journal of allergy and clinical immunology. 2010 Sep     [PubMed]
The diagnosis and management of anaphylaxis: an updated practice parameter. The Journal of allergy and clinical immunology. 2005 Mar     [PubMed]
Lanza FL,Chan FK,Quigley EM, Guidelines for prevention of NSAID-related ulcer complications. The American journal of gastroenterology. 2009 Mar     [PubMed]
Rhodes A,Evans LE,Alhazzani W,Levy MM,Antonelli M,Ferrer R,Kumar A,Sevransky JE,Sprung CL,Nunnally ME,Rochwerg B,Rubenfeld GD,Angus DC,Annane D,Beale RJ,Bellinghan GJ,Bernard GR,Chiche JD,Coopersmith C,De Backer DP,French CJ,Fujishima S,Gerlach H,Hidalgo JL,Hollenberg SM,Jones AE,Karnad DR,Kleinpell RM,Koh Y,Lisboa TC,Machado FR,Marini JJ,Marshall JC,Mazuski JE,McIntyre LA,McLean AS,Mehta S,Moreno RP,Myburgh J,Navalesi P,Nishida O,Osborn TM,Perner A,Plunkett CM,Ranieri M,Schorr CA,Seckel MA,Seymour CW,Shieh L,Shukri KA,Simpson SQ,Singer M,Thompson BT,Townsend SR,Van der Poll T,Vincent JL,Wiersinga WJ,Zimmerman JL,Dellinger RP, Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive care medicine. 2017 Mar     [PubMed]
Bookman MA,Kloth DD,Kover PE,Smolinski S,Ozols RF, Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Seminars in oncology. 1997 Dec     [PubMed]
Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016 Feb     [PubMed]
Crowther RS,Bellanger R,Szauter KE, In vitro stability of ranitidine hydrochloride in enteral nutrient formulas. The Annals of pharmacotherapy. 1995 Sep     [PubMed]
Allwood MC,H M, Factors influencing the stability of ranitidine in TPN mixtures. Clinical nutrition (Edinburgh, Scotland). 1995 Jun     [PubMed]
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2015 Nov     [PubMed]
Lam JR,Schneider JL,Zhao W,Corley DA, Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013 Dec 11     [PubMed]
Lai T,Wu M,Liu J,Luo M,He L,Wang X,Wu B,Ying S,Chen Z,Li W,Shen H, Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis. Pediatrics. 2018 Feb     [PubMed]
Song WJ,Kim MH,Lee SM,Kwon YE,Kim SH,Cho SH,Min KU,Kim YY,Chang YS, Two cases of h(2)-receptor antagonist hypersensitivity and cross-reactivity. Allergy, asthma     [PubMed]
Demirkan K,Bozkurt B,Karakaya G,Kalyoncu AF, Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. Journal of investigational allergology     [PubMed]
Park KH,Pai J,Song DG,Sim DW,Park HJ,Lee JH,Jeong KY,Pan CH,Shin I,Park JW, Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2016 Apr     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Nurse-Pharmacology PN. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Nurse-Pharmacology PN, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Nurse-Pharmacology PN, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Nurse-Pharmacology PN. When it is time for the Nurse-Pharmacology PN board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Nurse-Pharmacology PN.